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Abstract
Addition of lysophosphatidic acid (LPA) to rat aorta-derived endothelial cells significantly induced preproendothelin-1
(preproET-1) mRNA expression. PreproET-1 mRNA levels reached a plateau within 1 h after the addition of 0.5 WM LPA
and declined after 2 h. The induction was superinduced by cycloheximide and was blocked by actinomycin D. Suramin, an
LPA receptor antagonist, abolished the induction of preproET-1 mRNA by LPA. Protein kinase C inhibitors, H7 and
bisindolylmaleimide, were able to block the induction. Transient transfection experiment revealed that the elevated
preproET-1 mRNA was a result of the activation of ET-1 gene activity. Electrophoretic mobility shift assay revealed that
LPA stimulated the binding of AP-1. The secreted level of ET-1 was elevated 2.3-fold after 12 h of stimulation with LPA. Our
results suggest that the upregulation of preproET-1 by LPA may serve to augment and prolong the vasoconstriction action of
LPA. ß 1998 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Endothelin-1 (ET-1) is a very potent vasoconstric-
tor that has been initially isolated from the super-
natant of cultured porcine endothelial cells [1]. The
mRNA for preproET-1 is expressed in porcine aortic
endothelial cells in vivo [2] and human umbilical vein
endothelial cells in vitro [3]. Many physiological
stimuli were found to increase ET-1 production and
mRNA level, including thrombin [4], calcium iono-
phore [5], tumor promoter [5], insulin [6], bradykinin
[7], transforming growth factor-L [8], and interleukin-
1 [9]. We reported that angiotensin II stimulated ET-
1 production in rat heart endothelial cells [10].
Lysophosphatidic acid (LPA) is a bioactive phos-
pholipid that is released from activated platelets [11].
LPA has been reported to be involved in a number
of biological processes, including mitogenesis, adhe-
sion, and chemotaxis (for reviews, see [12^14]). LPA
receptors have been cloned by several groups of in-
vestigators [15^17]. The receptor couples to distinct
G proteins and stimulates the activation of Ras and
Rho proteins via di¡erent pathways [12,13].
LPA was found to be the lipid component in soy-
bean extract that was responsible for the vasopressor
activity in rats [18]. LPA was also found to exert a
vasopressor e¡ect on spontaneously hypertensive rats
and Wistar Kyoto rats [19]. These observations
prompted us to examine whether the e¡ect of LPA
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involves the induction of some other vasoconstriction
agents. Our results show that exposure of rat aorta-
derived endothelial cells (RAEC) to LPA is associ-
ated with a rapid induction of preproET-1 mRNA.
The increase in the expression and release of ET-1
may augment or prolong the action of LPA.
2. Materials and methods
2.1. Cell culture and materials
RAEC cultures were provided by Diglio et al. [20].
Cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM, Life Technologies) containing
10% fetal bovine serum (FBS), 2 mM L-glutamine,
and 25 Wg/ml gentamycin at 37‡C in a humidi¢ed
atmosphere of 5% CO2. Cells were serially subcul-
tured by treatment with 0.05% Trypsin and used
for experimentation between passages 12 and 20.
LPA, salmon testes DNA, polydIWpolydC, and H7
were obtained from Sigma (St. Louis, MO).
[32P]dCTP and [Q-32P]ATP were obtained from ICN
(Costa Mesa, CA). Ultraspec II reagent was obtained
from Biotecx (Houston, TX). ITS was purchased
from Collaborative Biomedical (Bedford, MA). Fetal
bovine serum was obtained from Bio£uids (Rock-
ville, MD). T4 kinase and AP-1 consensus sequence
were obtained from Promega (Madison, WI). Bisin-
dolylmaleimide-HCl (BIM) and suramin were pur-
chased from Calbiochem-Nova Biochem (La Jolla,
CA). Lipofectin and Opti-MEM were purchased
from Life Technologies (Grand Island, NY). Endo-
thelin ELISA kit was purchased from Cayman (Ann
Arbor, MI). All other reagents used were of the high-
est grade commercially available.
2.2. Northern blot analysis
Cells were seeded into 100 mm dishes containing
DMEM and 10% FBS. Near con£uent cells were
changed to serum-free DMEM supplemented with
ITS (1 WM insulin, 6.25 Wg/ml transferrin and 6.25
ng/ml selenous acid) for 24 h before the addition of
test agents. After the designated time, total RNA
was extracted using Ultraspec II reagent. Fifteen Wg
of RNA was denatured and separated by electropho-
resis on 1% agarose gel containing 2.2 M formalde-
hyde. Following transfer, the RNA was covalently
bound to GeneScreen (NEN, Boston, MA) by UV-
crosslinking. Hybridization and washing conditions
were carried out according to the method of Church
and Gilbert [21]. A rat ET-1 cDNA probe was gen-
erously provided by Dr. Tomoh Masaki and Dr. M.
Yanagisawa (Kyoto University) [22]. The cDNA was
labeled with [32P]dCTP using a random primer kit
from Amersham. The blots were exposed to Kodak
XAR-5 ¢lms with an intensifying screen. The inten-
sity of the bands was quantitated by a Digital Imag-
ing System (Alpha Innotech). The experiments were
repeated three to four times and representative data
were shown.
2.3. ET-1 promoter activity
RAEC cultures in 60 mm plates were transfected
with 4 Wg of 4.4 kb ET-1 promoter coupled to chlor-
amphenicol acetyltransferase (CAT) gene (provided
by Dr. Mu-En Lee, Harvard Medical School) [23],
pSV0CAT, or pSV2CAT. Transfection was carried
out with 32 Wg of lipofectin reagent in the presence
of Opti-MEM for 6 h. The medium was changed to
DMEM containing 10% FBS for 16 h. The cultures
were then incubated with serum-free DMEM in the
presence or absence of 0.5 WM LPA. After 36 h, cell
lysates were prepared, and aliquots containing the
same amount of protein were assayed for CAT ac-
tivities as described by Gorman et al. [24]. CAT ac-
tivities were quantitated by counting the radioactiv-
ity excised from the spots corresponding to
chloramphenicol and acetylated chloramphenicol.
2.4. Electrophoretic mobility shift assay
Nuclear extracts from control and LPA-treated
cells were prepared according to Andrews and Faller
[25]. AP-1 consensus sequence was end-labeled with
[Q-32P]ATP and T4 kinase. Binding reaction (20 Wl)
containing 5 Wg of nuclear extract, 1 Wg testes DNA,
1 Wg polydIWpolydC in 10 mM HEPES (pH 7.9), 10%
glycerol, 100 mM NaCl, 0.5 mM MgCl2, 0.8 mM
EDTA, 0.2 mM dithiothreitol and 0.08 mM phenyl-
methylsulfonyl £uoride, was preincubated at room
temperature with or without unlabeled AP-1 for
15 min. 32P-Labeled AP-1 (90 000 cpm) was then
added to the reaction and incubated at room temper-
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ature for another 20 min. The samples were resolved
on native 5% polyacrylamide gel at 4‡C with
0.5UTBE (1UTBE: 0.045 M Tris-borate, 1 mM
EDTA). The gel was dried and analyzed by autora-
diography.
2.5. Secreted levels of ET-1
RAEC cultures were plated in DMEM containing
10% FBS in 35 mm dishes. Near-con£uent cells were
maintained in serum-free DMEM with the addition
of ITS for 24 h before the addition of 1 WM LPA for
12 h. ET-1 released into the medium was measured
by a commercially available ELISA kit (Cayman)
using a Bio-Tek model EL311 microplate reader (Wi-
nooski, VT). The experiment was performed four
times.
2.6. Statistical analysis
Statistical analysis was made by the Student’s t-
test for comparison of any two sample means. Values
are expressed as means þ S.E.M. P-values 6 0.05
were considered statistically signi¢cant.
3. Results
Steady-state levels of preproET-1 mRNA were de-
termined in RAEC cultures by Northern blot analy-
sis. A speci¢c transcript of preproET-1 (2.4 kb) was
observed. The basal level of preproET-1 mRNA was
low (Fig. 1, lane 1). The mRNA level increased rap-
idly upon the addition of LPA. Levels of preproET-1
Fig. 1. Time course of preproET-1 mRNA induction in RAEC
cultures by LPA. Near-con£uent cultures were exposed to LPA
(1 WM) for the times indicated. Northern blot analysis was per-
formed as described in Section 2. Hybridization pattern of con-
trol cells (lane 1); cells treated with LPA for 15 min (lane 2);
30 min (lane 3); 1 h (lane 4); 2 h (lane 5); and 3 h (lane 6);
are shown. Fold of induction was determined by densitometric
scanning of preproET-1 mRNA band.
Fig. 2. Induction of preproET-1 mRNA as a function of LPA
dose. Near-con£uent RAEC cultures were treated with di¡erent
concentrations of LPA for 1 h. Northern blot analysis was per-
formed as described in Section 2. Hybridization patterns of
control cells (lane 1); cells treated with 0.5 WM (lane 2); 2 WM
(lane 3); 5 WM (lane 4); 10 WM LPA (lane 5); are shown. Fold
of induction was determined by densitometric scanning of pre-
proET-1 mRNA band.
Fig. 3. E¡ect of cycloheximide (CHX) and actinomycin D
(ActD) on the induction of preproET-1 mRNA by LPA. Near-
con£uent RAEC cultures were pretreated with CHX (20 Wg/ml)
or ActD (1 Wg/ml) for 30 min before the addition of 1 WM
LPA for 1 h. Northern blot analysis was performed as de-
scribed in Section 2. Hybridization patterns of control cells
(lane 1); cells treated with 1 WM LPA (lane 2); CHX (lane 3);
LPA and CHX (lane 4); ActD (lane 5); LPA and ActD (lane
6); are shown.
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mRNA increased 4.5-fold at 15 min (lane 2) and
declined over 2 h (lane 5). As shown in Fig. 2, pre-
proET-1 mRNA responded to LPA in a dose-de-
pendent manner. When the cells were stimulated
with 0.5 and 10 WM LPA, preproET-1 mRNA level
increased from 2.2- to 7.1-fold.
The next series of experiments were performed to
examine the mechanism of preproET-1 mRNA in-
duction. Inhibitors of protein and RNA synthesis
were included singly or in combination with LPA.
Cycloheximide was included to examine whether
the induction of preproET-1 gene is a direct e¡ect
of LPA or whether intermediate protein synthesis is
required. Cycloheximide alone induced preproET-1
mRNA (Fig. 3, lane 3). In the presence of LPA
and cycloheximide (lane 4), the induction was higher
than LPA alone (lane 2), implying that the induction
does not require de novo protein synthesis. In the
Fig. 5. E¡ect of PKC inhibitors on the induction of preproET-
1 mRNA by LPA. Near-con£uent RAEC cultures were pre-
treated with 5 WM H7 or 10 WM BIM for 30 min before the
addition of 1 WM LPA for 1 h. Northern blot analysis was per-
formed as described in Section 2. Hybridization patterns of
control cells (lane 1); cells treated with 1 WM LPA (lane 2); H7
(lane 3); LPA and H7 (lane 4); BIM (lane 5); LPA and BIM
(lane 6); are shown.
Fig. 4. E¡ect of suramin, an antagonist of LPA receptor, on
the induction of preproET-1 mRNA. RAEC cultures were pre-
treated with 100 WM suramin for 1 h before the addition of
LPA for 1 h. Northern blot analysis was performed as de-
scribed in Section 2. Hybridization patterns of control cells
(lane 1); cells treated with 1 WM LPA (lane 2); suramin (lane
3); LPA and suramin (lane 4); are shown. Fig. 6. Stimulation of ET-1 promoter activity by LPA. RAEC
cultures in 60 mm plates were transfected with 4 Wg of either
pSV0CAT, pSV2CAT or ET-1 promoter (34.4kCAT) and 32
Wg of Lipofectin reagent for 6 h. The medium was then
changed to DMEM in the presence or absence of 1 WM LPA
for 36 h prior to harvest for CAT assays. CAT activity of cells
transfected with pSV0CAT (lanes 1 and 2); pSV2CAT (lanes 3
and 4); and ET-1 promoter (lanes 5 and 6); are shown. Lanes
1, 3 and 5 represent the pattern in the absence of LPA; lanes
2, 4 and 6 represent the pattern in the presence of LPA.
Fig. 7. Activation of AP-1 binding by LPA. RAEC cultures
were treated with or without 1 WM LPA for 10 min before the
nuclear extracts were prepared for EMSA. Gel shift patterns of
nuclear extract from control cells (lane 1); and cells treated
with 1 WM LPA for 10 min (lane 2); are shown. Lanes 3 and 4
represent the binding pattern in the presence of 200-fold excess
of unlabeled AP-1.
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presence of actinomycin D, the induction was abol-
ished (lane 6), suggesting that de novo RNA synthe-
sis is required.
Suramin, a speci¢c antagonist for LPA receptor
[26], was included to examine if the e¡ect of LPA
is receptor-mediated. Fig. 4 shows that 100 WM sur-
amin pretreatment for 1 h could block the induction
(lane 4), indicating that the induction of preproET-1
mRNA is mediated by the LPA receptor.
One of the pathways of LPA is the activation of
phospholipase C, which in turn stimulates the activ-
ity of protein kinase C (PKC) [14]. To study whether
the induction of preproET-1 mRNA involves PKC,
speci¢c inhibitors of PKC were included. In this ex-
periment, cells were pretreated with 5 WM H7 [27] or
10 WM bisindolylmaleimide (BIM) [28] for 30 min
before the addition of LPA. Fig. 5 shows that both
H7 and BIM could block the induction of preproET-
1 mRNA (lanes 4 and 6), suggesting that the e¡ect of
LPA is mediated by a PKC-dependent pathway.
Expression of elevated ET-1 mRNA level after
LPA treatment may be the result of increased stabil-
ity of the message and/or activation of ET-1 gene
activity. To test whether the transcription rate of
ET-1 is altered by LPA, transfection experiments
were carried out with ET-1 promoter coupled to
the CAT gene in the absence or presence of LPA.
Fig. 6 shows that LPA increased CAT activity of ET-
1 promoter by four-fold (lanes 5 and 6). LPA had no
e¡ect on the CAT activities in cells transfected with
pSV0CAT (lanes 1 and 2) or pSV2CAT (lanes 3 and
4).
In order to examine the involvement of transcrip-
tion factor AP-1, EMSA was carried out on nuclear
extracts prepared from RAEC cultures treated with
or without LPA. Binding of AP-1 was activated after
10 min stimulation with LPA (Fig. 7, lane 2). The
speci¢city of the assay was demonstrated by the dis-
appearance of the band after the addition of excess
unlabeled AP-1 (lanes 3 and 4).
The release of ET-1 in response to LPA was de-
termined in the conditioned medium using an ELISA
kit. The amount of ET-1 released from cells treated
with LPA for 12 h was 2.3-fold that of the control
cells (108 þ 11 vs 47 þ 7 pg per 104 cells, respectively,
P6 0.05).
4. Discussion
The present study demonstrated that LPA acts on
RAEC culture to induce preproET-1 mRNA in a
dose- and time-dependent manner. The induction is
mediated by LPA receptor and involves a PKC-de-
pendent pathway. In addition, the increase of ET-1
mRNA correlated well with the release of ET-1 into
the conditioned medium. It is noted that the induc-
tion of preproET-1 mRNA begins with 0.5 WM LPA.
This concentration is close to the physiological level
of LPA [11].
The level of preproET-1 mRNA is ‘superinduced’
in the presence of cycloheximide and LPA. Pre-
proET-1 mRNA in the presence of cycloheximide
alone is higher than the basal level. Yanagisawa et
al. [1] reported the 3P-end of preproET-1 mRNA
contains several ‘AUUUA’ motifs that confer
mRNA instability.
Our data demonstrated that the induction of pre-
proET-1 mRNA by LPA could be attributed parti-
ally to transcriptional activation. The promoter of
the ET-1 gene has been shown to contain AP-1 sites
[29,30]. Our EMSA results showed that AP-1 binding
was activated after 10 min of stimulation with LPA.
Other elements responsible for the transcriptional ac-
tivation are under investigation.
LPA has been shown to activate a variety of sec-
ond messenger pathways, including activation of
PKC [14,31]. Yakubu et al. reported that the addi-
tion of factors produced by hemorrhaged blood
(such as LPA, serotonin, and thromboxane receptor
agonist U-46619), to piglet cerebral microvascular
endothelial cells resulted in an enhanced ET-1
production. These authors concluded that ET-1,
together with cerebral hematoma, could contribute
to enhanced cerebral constriction [32]. In this study
we demonstrate in RAEC cultures that LPA in-
duces ET-1 production by transcriptional activation.
The induction is mediated by a PKC-dependent
pathway.
In conclusion, we observed that ET-1 level is ele-
vated in LPA-treated RAEC cultures. The enhanced
production of ET-1 may augment and prolong the
action of LPA.
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